Translational cancer research is key for addressing, understanding and preventing cancer, a worldwide health concern despite the continuous advancement of research and treatment approaches.
The EU-funded TRANSCAN-3 project is bringing together 31 funding organisations from 20 countries, with the common goal of supporting high-impact translational cancer research. Through cross-national joint calls for proposals and making the most of international and interregional cooperation, TRANSCAN-3 aims to provide influential contributions as well as a sustainable model of funding for ground-breaking translational cancer research in Europe and beyond.
Project Information
Project Acronym: TRANSCAN-3 | Grant Agreement ID: 964264 |
Title: ERA-NET: Sustained collaboration of national and regional programmes in cancer research | EU Contribution: € 10,949,935.59 |
Type of action: ERA-NET-Cofund | Overall Budget: € 34,081,623.00 |
Funding Programme: Horizon 2020 Framework Programme | Duration: 60 months (Mar 2021 – Feb 2026) |
Call: H2020-SC1-BHC-2018-2020 | Coordinator: Ministero della Salute (Italy) |
Topic: SC1-HCO-14-2020 | Consortium: 31 partners |
Work Package Structure
TRANSCAN-3 will pursue its specific objectives through the implementation of seven highly-integrated work packages (WP). Four of them with overarching activities (WP1, WP4, WP5 and WP7).
TRANSCAN-3 Workpackage StructureGovernance Structure
The governance structure of TRANSCAN-3 is shown in the following image. Its governance structure is designed to allow the project to be executed and implemented in an efficient and transparent manner.
TRANSCAN-3 Governance Structure